URGN
UroGenBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The supported bull case is that UroGen now has two meaningful value drivers at once: ZUSDURI reimbursement friction improved after the January 1, 2026 J-code effective date, and UGN-103 has a defined regulatory path after the UTOPIA data. If launch metrics keep compounding and the NDA timeline holds, the stock has room to move toward a more development-plus-commercial multiple.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -2.9.
What can break
Cash, cash equivalents, and marketable securities were $120.5 million at December 31, 2025, while net loss was $153.5 million for 2025, keeping funding and cash-burn monitoring important.
Momentum
92
Value
41
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.00 · Bull $33.00 · Bear $16.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-28 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $35.63
Why
Momentum92 · Δ7d -2.9
Value41 · Δ7d +0.1
Sentiment46 · Δ7d +9.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
92
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.9
Δ21d
-0.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
46
33% active weight
Current posture
7d trendImproving
Δ7d
+9.2
Δ21d
+20.4
Why this grade
Composite grade B. Momentum 92.0 / Value 41.1 / Sentiment 45.8
Fundamentals (TTM)As of 2026-05-28
Fundamentals (TTM)
As of 2026-05-28
Market Cap
$1.4B
Beta
1.35
Shares Out
46.81M
P/E (TTM) · Derived
-9.4
P/S (TTM)
10.73
P/FCF (TTM) · Derived
-10.88
Rev YoY
+9.0%
EPS YoY
-26.3%
Gross Margin
+88.0%
Op Margin
-138.2%
Net Debt
-$112.61M
Current Ratio
3.99
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology